The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan
- 1 September 2008
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 76 (6) , 763-772
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Recent advances in understanding Marfan syndrome: Should we now treat surgical patients with losartan?The Journal of Thoracic and Cardiovascular Surgery, 2008
- Rationale and design of a randomized clinical trial of β-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndromeAmerican Heart Journal, 2007
- Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan SyndromeScience, 2006
- Old Drug, New Hope for Marfan SyndromeScience, 2006
- Candesartan CilexetilDrugs, 2005
- UDP-GlucuronosyltransferasesCurrent Drug Metabolism, 2000
- Characterization of Conjugated Metabolites of a New Angiotensin II Receptor Antagonist, Candesartan Cilexetil, in Rats by Liquid Chromatography/Electrospray Tandem Mass Spectrometry Following Chemical DerivatizationJournal of Mass Spectrometry, 1996
- Characterization of glucuronic acid conjugates of a novel angiotensin receptor antagonistRapid Communications in Mass Spectrometry, 1994
- Cardiovascular effects of GR117289, a novel angiotensin AT1 receptor antagonistBritish Journal of Pharmacology, 1994
- Pharmacological profile of GR117289 in vitro: a novel, potent and specific non‐peptide angiotensin AT1 receptor antagonistBritish Journal of Pharmacology, 1992